Base de dados : MEDLINE
Pesquisa : D02.705.400.625.050 [Categoria DeCS]
Referências encontradas : 1526 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 153 ir para página                         

  1 / 1526 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29277777
[Au] Autor:Koukourakis MI; Giatromanolaki A; Fylaktakidou K; Kouroupi M; Sivridis E; Zois CE; Kalamida D; Mitrakas A; Pouliliou S; Karagounis IV; Simopoulos K; Ferguson DJP; Harris AL
[Ad] Endereço:Department of Radiotherapy/Oncology, Democritus University of Thrace/University General Hospital of Alexandroupolis, Alexandroupolis, Greece targ@her.forthnet.gr.
[Ti] Título:Amifostine Protects Mouse Liver Against Radiation-induced Autophagy Blockage.
[So] Source:Anticancer Res;38(1):227-238, 2018 01.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: Amifostine is the only selective normal tissue cytoprotector, approved for the protection against platinum toxicities and radiotherapy-induced xerostomia. Free radical scavenger and DNA repair activities have been attributed to the drug. MATERIALS AND METHODS: We investigated the effect of amifostine on autophagy, lysosomal biogenesis and lipophagy of normal mouse liver exposed to clinically relevant doses of radiation. RESULTS: The study provides evidence that ionizing radiation blocks autophagy activity and lysosomal biogenesis in normal mouse liver. Amifostine, protects the liver autophagic machinery and induces lysosomal biogenesis. By suppressing autophagy, ionizing radiation induces lipid droplet accumulation, while pre-treatment with amifostine protects lipophagy and up-regulates the TIP47 protein and mRNA levels, showing a maintenance of lipid metabolism in the liver cells. CONCLUSION: It is concluded that amifostine, aside to DNA protection activity, exerts its cytoprotective function by preventing radiation-induced blockage of autophagy, lysosomal biogenesis and lipophagy.
[Mh] Termos MeSH primário: Amifostina/farmacologia
Fígado/efeitos dos fármacos
Protetores contra Radiação/farmacologia
[Mh] Termos MeSH secundário: Animais
Autofagia/efeitos dos fármacos
Raios gama
Metabolismo dos Lipídeos/efeitos dos fármacos
Fígado/metabolismo
Fígado/efeitos da radiação
Fígado/ultraestrutura
Lisossomos/metabolismo
Masculino
Camundongos Endogâmicos BALB C
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Radiation-Protective Agents); M487QF2F4V (Amifostine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180105
[Lr] Data última revisão:
180105
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171227
[St] Status:MEDLINE


  2 / 1526 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28759701
[Au] Autor:Riley P; Glenny AM; Hua F; Worthington HV
[Ad] Endereço:Cochrane Oral Health, Division of Dentistry, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, JR Moore Building, Oxford Road, Manchester, UK, M13 9PL.
[Ti] Título:Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy.
[So] Source:Cochrane Database Syst Rev;7:CD012744, 2017 07 31.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Salivary gland dysfunction is an 'umbrella' term for the presence of either xerostomia (subjective sensation of dryness), or salivary gland hypofunction (reduction in saliva production). It is a predictable side effect of radiotherapy to the head and neck region, and is associated with a significant impairment of quality of life. A wide range of pharmacological interventions, with varying mechanisms of action, have been used for the prevention of radiation-induced salivary gland dysfunction. OBJECTIVES: To assess the effects of pharmacological interventions for the prevention of radiation-induced salivary gland dysfunction. SEARCH METHODS: Cochrane Oral Health's Information Specialist searched the following databases: Cochrane Oral Health's Trials Register (to 14 September 2016); the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 8) in the Cochrane Library (searched 14 September 2016); MEDLINE Ovid (1946 to 14 September 2016); Embase Ovid (1980 to 14 September 2016); CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature; 1937 to 14 September 2016); LILACS BIREME Virtual Health Library (Latin American and Caribbean Health Science Information database; 1982 to 14 September 2016); Zetoc Conference Proceedings (1993 to 14 September 2016); and OpenGrey (1997 to 14 September 2016). We searched the US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov) and the World Health Organization International Clinical Trials Registry Platform for ongoing trials. No restrictions were placed on the language or date of publication when searching the electronic databases. SELECTION CRITERIA: We included randomised controlled trials, irrespective of their language of publication or publication status. Trials included participants of all ages, ethnic origin and gender, scheduled to receive radiotherapy on its own or in addition to chemotherapy to the head and neck region. Participants could be outpatients or inpatients. We included trials comparing any pharmacological agent regimen, prescribed prophylactically for salivary gland dysfunction prior to or during radiotherapy, with placebo, no intervention or an alternative pharmacological intervention. Comparisons of radiation techniques were excluded. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We included 39 studies that randomised 3520 participants; the number of participants analysed varied by outcome and time point. The studies were ordered into 14 separate comparisons with meta-analysis only being possible in three of those.We found low-quality evidence to show that amifostine, when compared to a placebo or no treatment control, might reduce the risk of moderate to severe xerostomia (grade 2 or higher on a 0 to 4 scale) at the end of radiotherapy (risk ratio (RR) 0.35, 95% confidence interval (CI) 0.19 to 0.67; P = 0.001, 3 studies, 119 participants), and up to three months after radiotherapy (RR 0.66, 95% CI 0.48 to 0.92; P = 0.01, 5 studies, 687 participants), but there is insufficient evidence that the effect is sustained up to 12 months after radiotherapy (RR 0.70, 95% CI 0.40 to 1.23; P = 0.21, 7 studies, 682 participants). We found very low-quality evidence that amifostine increased unstimulated salivary flow rate up to 12 months after radiotherapy, both in terms of mg of saliva per 5 minutes (mean difference (MD) 0.32, 95% CI 0.09 to 0.55; P = 0.006, 1 study, 27 participants), and incidence of producing greater than 0.1 g of saliva over 5 minutes (RR 1.45, 95% CI 1.13 to 1.86; P = 0.004, 1 study, 175 participants). However, there was insufficient evidence to show a difference when looking at stimulated salivary flow rates. There was insufficient (very low-quality) evidence to show that amifostine compromised the effects of cancer treatment when looking at survival measures. There was some very low-quality evidence of a small benefit for amifostine in terms of quality of life (10-point scale) at 12 months after radiotherapy (MD 0.70, 95% CI 0.20 to 1.20; P = 0.006, 1 study, 180 participants), but insufficient evidence at the end of and up to three months postradiotherapy. A further study showed no evidence of a difference at 6, 12, 18 and 24 months postradiotherapy. There was low-quality evidence that amifostine is associated with increases in: vomiting (RR 4.90, 95% CI 2.87 to 8.38; P < 0.00001, 5 studies, 601 participants); hypotension (RR 9.20, 95% CI 2.84 to 29.83; P = 0.0002, 3 studies, 376 participants); nausea (RR 2.60, 95% CI 1.81 to 3.74; P < 0.00001, 4 studies, 556 participants); and allergic response (RR 7.51, 95% CI 1.40 to 40.39; P = 0.02, 3 studies, 524 participants).We found insufficient evidence (that was of very low quality) to determine whether or not pilocarpine performed better or worse than a placebo or no treatment control for the outcomes: xerostomia, salivary flow rate, survival, and quality of life. There was some low-quality evidence that pilocarpine was associated with an increase in sweating (RR 2.98, 95% CI 1.43 to 6.22; P = 0.004, 5 studies, 389 participants).We found insufficient evidence to determine whether or not palifermin performed better or worse than placebo for: xerostomia (low quality); survival (moderate quality); and any adverse effects.There was also insufficient evidence to determine the effects of the following interventions: biperiden plus pilocarpine, Chinese medicines, bethanechol, artificial saliva, selenium, antiseptic mouthrinse, antimicrobial lozenge, polaprezinc, azulene rinse, and Venalot Depot (coumarin plus troxerutin). AUTHORS' CONCLUSIONS: There is some low-quality evidence to suggest that amifostine prevents the feeling of dry mouth in people receiving radiotherapy to the head and neck (with or without chemotherapy) in the short- (end of radiotherapy) to medium-term (three months postradiotherapy). However, it is less clear whether or not this effect is sustained to 12 months postradiotherapy. The benefits of amifostine should be weighed against its high cost and side effects. There was insufficient evidence to show that any other intervention is beneficial.
[Mh] Termos MeSH primário: Radioterapia/efeitos adversos
Doenças das Glândulas Salivares/prevenção & controle
Xerostomia/prevenção & controle
[Mh] Termos MeSH secundário: Amifostina/uso terapêutico
Medicamentos de Ervas Chinesas/uso terapêutico
Feminino
Fator 7 de Crescimento de Fibroblastos/uso terapêutico
Seres Humanos
Masculino
Pilocarpina/uso terapêutico
Qualidade de Vida
Protetores contra Radiação/efeitos adversos
Protetores contra Radiação/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Saliva Artificial
Doenças das Glândulas Salivares/etiologia
Glândulas Salivares/efeitos da radiação
Salivação/efeitos dos fármacos
Salivação/efeitos da radiação
Xerostomia/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Drugs, Chinese Herbal); 0 (Radiation-Protective Agents); 0 (Saliva, Artificial); 01MI4Q9DI3 (Pilocarpine); 126469-10-1 (Fibroblast Growth Factor 7); M487QF2F4V (Amifostine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170801
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD012744


  3 / 1526 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28392886
[Au] Autor:Wu SZ; Tao LY; Wang JN; Xu ZQ; Wang J; Xue YJ; Huang KY; Lin JF; Li L; Ji KT
[Ad] Endereço:Department of Cardiology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou 325000, China.
[Ti] Título:Amifostine Pretreatment Attenuates Myocardial Ischemia/Reperfusion Injury by Inhibiting Apoptosis and Oxidative Stress.
[So] Source:Oxid Med Cell Longev;2017:4130824, 2017.
[Is] ISSN:1942-0994
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The present study was aimed at investigating the effect of amifostine on myocardial ischemia/reperfusion (I/R) injury of mice and H9c2 cells cultured with TBHP (tert-butyl hydroperoxide). The results showed that pretreatment with amifostine significantly attenuated cell apoptosis and death, accompanied by decreased reactive oxygen species (ROS) production and lower mitochondrial potential (ΔΨm). In vivo, amifostine pretreatment alleviated I/R injury and decreased myocardial apoptosis and infarct area, which was paralleled by increased superoxide dismutase (SOD) and reduced malondialdehyde (MDA) in myocardial tissues, increased Bcl2 expression, decreased Bax expression, lower cleaved caspase-3 level, fewer TUNEL positive cells, and fewer DHE-positive cells in heart. Our results indicate that amifostine pretreatment has a protective effect against myocardial I/R injury via scavenging ROS.
[Mh] Termos MeSH primário: Amifostina/farmacologia
Amifostina/uso terapêutico
Apoptose/efeitos dos fármacos
Traumatismo por Reperfusão Miocárdica/tratamento farmacológico
Estresse Oxidativo/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Sobrevivência Celular/efeitos dos fármacos
Células Cultivadas
Modelos Animais de Doenças
Camundongos
Mitocôndrias/efeitos dos fármacos
Traumatismo por Reperfusão Miocárdica/prevenção & controle
Profilaxia Pré-Exposição
Protetores contra Radiação/farmacologia
Protetores contra Radiação/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Radiation-Protective Agents); M487QF2F4V (Amifostine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170621
[Lr] Data última revisão:
170621
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170411
[St] Status:MEDLINE
[do] DOI:10.1155/2017/4130824


  4 / 1526 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27884394
[Au] Autor:Montani D; Chaumais MC; Seferian A; Humbert M
[Ad] Endereço:Université Paris-Sud, université Paris-Saclay, faculté de médecine, 78, rue du Général-Leclerc, 94270 Le Kremlin Bicêtre, France; Hôpital de Bicêtre, AP-HP, centre de référence de l'hypertension pulmonaire sévère, département hospitalo-universitaire (DHU) thorax innovation (Torino), service de pneum
[Ti] Título:[Mitomycin-induced pulmonary veno-occlusive disease: A rare but severe complication].
[Ti] Título:La maladie veino-occlusive pulmonaire induite par la mitomycine : une complication rare mais sévère..
[So] Source:Bull Cancer;104(2):202-204, 2017 Feb.
[Is] ISSN:1769-6917
[Cp] País de publicação:France
[La] Idioma:fre
[Mh] Termos MeSH primário: Antibióticos Antineoplásicos/efeitos adversos
Mitomicina/efeitos adversos
Pneumopatia Veno-Oclusiva/induzido quimicamente
[Mh] Termos MeSH secundário: Amifostina/uso terapêutico
Animais
Neoplasias do Ânus/tratamento farmacológico
Seres Humanos
Hipertensão Pulmonar/induzido quimicamente
Pneumopatia Veno-Oclusiva/genética
Pneumopatia Veno-Oclusiva/prevenção & controle
Protetores contra Radiação/uso terapêutico
Ratos
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Antibiotics, Antineoplastic); 0 (Radiation-Protective Agents); 50SG953SK6 (Mitomycin); M487QF2F4V (Amifostine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170213
[Lr] Data última revisão:
170213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161126
[St] Status:MEDLINE


  5 / 1526 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27762064
[Au] Autor:Zhang F; Yang B; Zhang K; Hou ML; Lu XC; Li YX
[Ad] Endereço:National Engineering Laboratory for Drug gable Gene and Protein Screening, Northeast Normal University, Changchun, Jilin, China.
[Ti] Título:CCND1-BCL2 Gene Network: A direct target of Amifostine in human acute megakaryocytic leukemia cells.
[So] Source:Chem Biol Drug Des;89(5):681-693, 2017 May.
[Is] ISSN:1747-0285
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Amifostine, 2-(3-aminopropyl) aminoethyl phosphorothioate, is a broad-spectrum cytoprotective agent used to treat nuclear radiation and chemical weapon injuries. Recently, amifostine has been shown to have a profound biological influence on tumor cells. To examine the effects and mechanisms underlying the effects of amifostine on human acute megakaryocytic leukemia, we evaluated the efficacy of amifostine against Dami cells and observed a cell cycle arrest in G /M phase. Amifostine treatment also induced cell apoptosis of Dami cells which corresponds to formal studies. Through whole-genome microarray and bioinformatics analyses, we found that amifostine affected the gene expression of CCND1, BCL2, and CASP3 which revealed the mechanism amifostine acted on Dami cells. Thus, CCND1-BCL2 Gene Network is predicted to be a direct target of amifostine treating human acute megakaryocytic leukemia, which may provide a novel potential target for the therapy of several subtypes of human AML.
[Mh] Termos MeSH primário: Amifostina/química
Antineoplásicos/química
Ciclina D1/metabolismo
Proteínas Proto-Oncogênicas c-bcl-2/metabolismo
[Mh] Termos MeSH secundário: Amifostina/farmacologia
Antineoplásicos/farmacologia
Apoptose/efeitos dos fármacos
Linhagem Celular Tumoral
Proliferação Celular
Análise por Conglomerados
Ciclina D1/antagonistas & inibidores
Pontos de Checagem da Fase G2 do Ciclo Celular/efeitos dos fármacos
Expressão Gênica/efeitos dos fármacos
Redes Reguladoras de Genes/efeitos dos fármacos
Seres Humanos
Leucemia Megacarioblástica Aguda/metabolismo
Leucemia Megacarioblástica Aguda/patologia
Pontos de Checagem da Fase M do Ciclo Celular/efeitos dos fármacos
Mapas de Interação de Proteínas/efeitos dos fármacos
Proteínas Proto-Oncogênicas c-bcl-2/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (CCND1 protein, human); 0 (Proto-Oncogene Proteins c-bcl-2); 136601-57-5 (Cyclin D1); M487QF2F4V (Amifostine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170509
[Lr] Data última revisão:
170509
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161021
[St] Status:MEDLINE
[do] DOI:10.1111/cbdd.12889


  6 / 1526 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28266200
[Au] Autor:Emir S; Özyörük D; Arman Ö; Özbek N; Tunç B
[Ad] Endereço:Ankara Children's Hematology/Oncology Training and Research Hospital, Ankara, Turkey.
[Ti] Título:Accidental cisplatin overdose in a child: Successful management with repetitive plasmapheresis and use of chemoprotective agents.
[So] Source:Turk J Pediatr;58(3):315-317, 2016.
[Is] ISSN:0041-4301
[Cp] País de publicação:Turkey
[La] Idioma:eng
[Ab] Resumo:Cisplatin is one of the effective chemotherapeutic agents widely used for many tumor types in children. The most serious complications of cisplatin overdose are nephrotoxicity and ototoxicity. It may lead to life-threatening complications and even death. We report a 13-year-old female patient with osteosarcoma who received a massive cisplatin overdose mistakenly. She was given cisplatin 120 mg/m2/day for consecutive two days, instead of one day (total 240 mg/m2) due to a prescription error. After 12 hours, her cisplatin level was measured as 8,500 ng/ml (normal: 1,000-5,000 ng/ml). She was treated with repeated plasmapheresis combined with use of two chemoprotectants, (N-acetylcysteine and amifostine). On her follow up, renal functions and audiometric tests remained normal. According to our experience with our case, early urgent combined treatment is very important in the management of cisplatin overdose.
[Mh] Termos MeSH primário: Acetilcisteína/uso terapêutico
Amifostina/uso terapêutico
Antineoplásicos/efeitos adversos
Cisplatino/efeitos adversos
Overdose de Drogas/terapia
Plasmaferese/métodos
[Mh] Termos MeSH secundário: Adolescente
Antineoplásicos/administração & dosagem
Cisplatino/administração & dosagem
Feminino
Seres Humanos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); M487QF2F4V (Amifostine); Q20Q21Q62J (Cisplatin); WYQ7N0BPYC (Acetylcysteine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170626
[Lr] Data última revisão:
170626
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170308
[St] Status:MEDLINE


  7 / 1526 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27855533
[Au] Autor:Wu HY; Hu ZH; Jin T
[Ad] Endereço:a Department of Radiation Oncology , Shanghai Pulmonary Hospital, Tongji University School of Medicine , Shanghai , People's Republic of China and.
[Ti] Título:Sustained-release microspheres of amifostine for improved radio-protection, patient compliance, and reduced side effects.
[So] Source:Drug Deliv;23(9):3704-3711, 2016 Nov.
[Is] ISSN:1521-0464
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A biweekly administration of sustained-release microsphere dosage form of amifostine, a radioprotective drug used in radiotherapy, was performed to examine the feasibility to minimize injection frequency and blood concentration-associated side effects. Model animal trials indicated that this subcutaneously injecting microspheres, 50-100 µm in diameter, achieved bi-weekly prolonged radio-protective efficacy and, at the same time, significantly reduced skin irritation than the solution form of amifostine given by the same administration route. In addition, the hypertension associated with blood concentration of amifostine was not observed in the drug-treated rats. The animals given the amifostine microspheres and amifostine showed significantly differences in white blood cell, red blood cell, hematocrit, hemoglobin and spleen tissue histopathology after exposed under a cobalt-60 γ-radiation at a dose rate of 1.0 Gy/min for 6 min. The in vitro release profile of amifostine from the micropsheres showed a minor initial burst (less than 20% of total drug loading in the first day of administration), consisting with the side effects observations. The results suggest that amifostine encapsulated in sustained-release microspheres may be an ideal dosage form for prolonged radio-protective efficacy and improved patient compliance.
[Mh] Termos MeSH primário: Amifostina/administração & dosagem
Amifostina/efeitos adversos
Preparações de Ação Retardada/administração & dosagem
Preparações de Ação Retardada/efeitos adversos
Protetores contra Radiação/administração & dosagem
Protetores contra Radiação/efeitos adversos
[Mh] Termos MeSH secundário: Amifostina/química
Animais
Preparações de Ação Retardada/química
Seres Humanos
Injeções Subcutâneas/métodos
Masculino
Camundongos
Microesferas
Tamanho da Partícula
Cooperação do Paciente
Protetores contra Radiação/química
Radioterapia/efeitos adversos
Ratos
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Delayed-Action Preparations); 0 (Radiation-Protective Agents); M487QF2F4V (Amifostine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170224
[Lr] Data última revisão:
170224
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161119
[St] Status:MEDLINE


  8 / 1526 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27585945
[Au] Autor:Cakmak G; Severcan M; Zorlu F; Severcan F
[Ad] Endereço:a Department of Biology, Faculty of Arts and Sciences , Duzce University , Duzce , Turkey.
[Ti] Título:Structural and functional damages of whole body ionizing radiation on rat brain homogenate membranes and protective effect of amifostine.
[So] Source:Int J Radiat Biol;92(12):837-848, 2016 Dec.
[Is] ISSN:1362-3095
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To investigate the effects of whole body ionizing radiation at a sublethal dose on rat brain homogenate membranes and the protective effects of amifostine on these systems at molecular level. MATERIALS AND METHODS: Sprague-Dawley rats, in the absence and presence of amifostine, were whole-body irradiated at a single dose of 8 Gy and decapitated after 24 h. The brain homogenate membranes of these rats were analyzed using Fourier Transform Infrared (FTIR) spectroscopy. RESULTS: Ionizing radiation caused a significant increase in the lipid to protein ratio and significant decreases in the ratios of olefinic = CH/lipid, CH /lipid, carbonyl ester/lipid and CH /lipid suggesting, respectively, a more excessive decrease in the protein content and the degradation of lipids as a result of lipid peroxidation. In addition, radiation changed the secondary structure of proteins and the status of packing of membrane lipid head groups. Furthermore, it caused a decrease in lipid order and an increase in membrane fluidity. The administration of amifostine before ionizing radiation inhibited all the radiation-induced alterations in brain homogenate membranes. CONCLUSIONS: The results revealed that whole body ionizing radiation at a sublethal dose causes significant alterations in the structure, composition and dynamics of brain homogenate membranes and amifostine has a protective effect on these membranes.
[Mh] Termos MeSH primário: Amifostina/administração & dosagem
Lesões Encefálicas/metabolismo
Lesões Encefálicas/prevenção & controle
Lipídeos de Membrana/metabolismo
Proteínas de Membrana/metabolismo
Lesões por Radiação/metabolismo
Lesões por Radiação/prevenção & controle
[Mh] Termos MeSH secundário: Animais
Encéfalo/metabolismo
Encéfalo/patologia
Encéfalo/efeitos da radiação
Lesões Encefálicas/etiologia
Masculino
Fluidez de Membrana/efeitos dos fármacos
Fluidez de Membrana/efeitos da radiação
Dose de Radiação
Lesões por Radiação/etiologia
Protetores contra Radiação/administração & dosagem
Ratos
Ratos Sprague-Dawley
Irradiação Corporal Total/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Membrane Lipids); 0 (Membrane Proteins); 0 (Radiation-Protective Agents); M487QF2F4V (Amifostine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM; S
[Da] Data de entrada para processamento:160903
[St] Status:MEDLINE


  9 / 1526 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27121071
[Au] Autor:Bougioukas I; Didilis V; Emigholz J; Waldmann-Beushausen R; Stojanovic T; Mühlfeld C; Schoendube FA; Danner BC
[Ad] Endereço:Department of Thoracic and Cardiovascular Surgery, University Medical Center, Göttingen, Germany ybougioukas@yahoo.com.
[Ti] Título:The effect of amifostine on lung ischaemia-reperfusion injury in rats.
[So] Source:Interact Cardiovasc Thorac Surg;23(2):273-9, 2016 08.
[Is] ISSN:1569-9285
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Lung ischaemia-reperfusion injury (LIRI) frequently occurs after lung transplantation or cardiac surgery with cardiopulmonary bypass, thus increasing postoperative morbidity and mortality. As LIRI is associated with the release of reactive oxygen species and a subsequent inflammatory reaction, we tested whether amifostine, a thiol and free radical scavenger, has a beneficial effect on LIRI. METHODS: A total number of 72 Wistar rats were subjected to LIRI with or without a single or double dose of amifostine (100 mg/kg, intraperitoneally). Experimental induction of LIRI was performed by clamping either the left lung hilum or the pulmonary artery alone for 60 min, followed by 90 min of reperfusion. Control groups consisted of LIRI and NaCl, a sham group and a no intervention group (baseline). At the end of the experiments, the left lung was analysed by quantitative RT-PCR of inflammatory marker gene expression, western blot of activated nuclear factor-κB (NF-κB) and light and electron microscopy. RESULTS: In placebo and amifostine groups, the expression levels of pro-inflammatory markers were increased significantly and to a similar extent independent of the type of ischaemia induction. In contrast, amifostine reduced the activation of NF-κB in comparison with placebo. This effect was present independent of the type of ischaemia or the application of a single or double dose of amifostine. However, oedema formation, blood-gas barrier damage and inflammatory reaction were similar in all amifostine or placebo LIRI groups. CONCLUSIONS: Despite a significant reduction in NF-κB activation, amifostine failed to decrease the inflammatory response and structural changes induced by LIRI in this experimental setting.
[Mh] Termos MeSH primário: Amifostina/farmacologia
Isquemia/tratamento farmacológico
Pulmão/irrigação sanguínea
Traumatismo por Reperfusão/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Modelos Animais de Doenças
Mediadores da Inflamação/metabolismo
Isquemia/metabolismo
Masculino
NF-kappa B/metabolismo
Ratos
Ratos Wistar
Espécies Reativas de Oxigênio/metabolismo
Traumatismo por Reperfusão/diagnóstico
Traumatismo por Reperfusão/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Inflammation Mediators); 0 (NF-kappa B); 0 (Reactive Oxygen Species); M487QF2F4V (Amifostine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171126
[Lr] Data última revisão:
171126
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160429
[St] Status:MEDLINE
[do] DOI:10.1093/icvts/ivw105


  10 / 1526 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27070667
[Au] Autor:Monson LA; Nelson NS; Donneys A; Farberg AS; Tchanque-Fossuo CN; Deshpande SS; Buchman SR
[Ad] Endereço:From the *Craniofacial Research Laboratory, Plastic Surgery Section, University of Michigan, Ann Arbor, MI; and †Department of Surgery, Plastic Surgery Section, Baylor College of Medicine, Houston, TX.
[Ti] Título:Amifostine Treatment Mitigates the Damaging Effects of Radiation on Distraction Osteogenesis in the Murine Mandible.
[So] Source:Ann Plast Surg;77(2):164-8, 2016 Aug.
[Is] ISSN:1536-3708
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:According to the American Society of Clinical Oncology, in 2012, more than 53,000 new cases of head and neck cancers (HNCs) were reported in the United States alone and nearly 12,000 deaths occurred relating to HNC. Although radiotherapy (XRT) has increased survival, the adverse effects can be unrelenting and their management is rarely remedial. Current treatment dictates surgical mandibular reconstruction using free tissue transfer. These complex operations entail extended hospitalizations and attendant complications often lead to delays in initiation of adjuvant therapy, jeopardizing prognosis as well as quality of life. The creation of new bone by distraction osteogenesis (DO) generates a replacement of deficient tissue from local substrate and could have immense potential therapeutic ramifications. Radiotherapy drastically impairs bone healing, precluding its use as a reconstructive method for HNC. We posit that the deleterious effects of XRT on bone formation could be pharmacologically mitigated. To test this hypothesis, we used a rodent model of DO and treated with amifostine, a radioprotectant, to assuage the XRT-induced injury on new bone formation. Amifostine had a profound salutary effect on bone regeneration, allowing the successful implementation of DO as a reconstructive technique. The optimization of bone regeneration in the irradiated mandible has immense potential for translation from the bench to the bedside, providing improved therapeutic options for patients subjected to XRT.
[Mh] Termos MeSH primário: Amifostina/farmacologia
Regeneração Óssea/efeitos dos fármacos
Mandíbula/efeitos dos fármacos
Osteogênese por Distração
Lesões por Radiação/tratamento farmacológico
Protetores contra Radiação/farmacologia
Radioterapia/efeitos adversos
[Mh] Termos MeSH secundário: Amifostina/administração & dosagem
Amifostina/uso terapêutico
Animais
Regeneração Óssea/efeitos da radiação
Masculino
Mandíbula/efeitos da radiação
Mandíbula/cirurgia
Protetores contra Radiação/administração & dosagem
Protetores contra Radiação/uso terapêutico
Distribuição Aleatória
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Radiation-Protective Agents); M487QF2F4V (Amifostine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170913
[Lr] Data última revisão:
170913
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160413
[St] Status:MEDLINE
[do] DOI:10.1097/SAP.0000000000000276



página 1 de 153 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde